First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan.

 
  Unprecedented Evidence for the Effectiveness of Hypertension Treatment 
    Valsartan in Preventing Cardiovascular Events in Japanese Patients 
 
 

TOKYO, April 26 /Xinhua-PRNewswire/ -- The clinical outcomes of the JIKEI HEART Study, the large-scale clinical trial headed by the Jikei University School of Medicine, was today published in the internationally renowned medical journal The Lancet. The study, involving more than 3,000 patients, is one of the largest cardiovascular intervention trials conducted in a Japanese population under realistic clinical settings. It also is the first large- scale study evaluating the benefits of the ARB, valsartan, in Japanese patients.

In the study, valsartan was added to conventional therapy to control blood pressure and protect against cardiovascular events and stroke. The results showed significant benefit with the use of valsartan, including a 39 decrease in…